Featuring a slide presentation from Dr Julia Rotow, including the following topics:
- Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00)
- Key findings from the Phase III HARMONi-6 study; ongoing Phase III HARMONi-3 study (5:12)
- Key findings from the Phase III HARMONi-2 study; ongoing Phase III HARMONi-7 study (9:59)
- Clinician insights about the potential role of ivonescimab in the front-line setting (12:02)
- Impetus for investigating ivonescimab in the relapsed/refractory (R/R) EGFR-mutant setting (14:01)
- Key findings from the Phase III HARMONi-A and HARMONi studies (16:07)
- Clinician insights about the potential role of ivonescimab in the treatment of R/R EGFR-mutant NSCLC; other novel PD-1/PD-L1 x VEGF bispecific antibodies under investigation (20:30)